Comparative Pharmacology
Head-to-head clinical analysis: REVLIMID versus THALIDOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVLIMID versus THALIDOMIDE.
REVLIMID vs THALIDOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and bFGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
None Documented
None Documented
Clinical Note
moderateThalidomide + Digoxin
"Thalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThalidomide + Digitoxin
"Thalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThalidomide + Deslanoside
"Thalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThalidomide + Acetyldigitoxin
"Thalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life of approximately 3-5 hours in patients with normal renal function. Half-life is prolonged in renal impairment (up to 9 hours in severe impairment).
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Primarily renal excretion as unchanged drug (approximately 67% of the dose in urine over 24 hours) with minor fecal elimination (<4%).
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Category C
Category D/X
Immunomodulatory Agent
Immunomodulatory Agent